 |
| About Bioline | All Journals | Testimonials | Membership | News |
|
||||||
|
||||||
RESEARCH NOTE A Nationwide Effort to Sistematically Monitor HIV-1 Diversity in Brazil: Preliminary Results
B Galv o-Castro/^+, JC Couto-Fernandez, MA Mello, MI Linhares-de- Carvalho*, LR Castello-Branco*/**, V Bongertz**, PCP Ferreira***, M Morgado**, E Sabino****, A Tanuri*****, the Brazilian Network for the HIV-1 Isolation and Characterization^++
Laboratorio Avancado de Saude Publica, Centro de Pesquisa Goncalo Moniz-FIOCRUZ, Rua Valdemar Falc o 121, 40295-001 Salvador, BA, Brasil *Ambulatorio da Providencia da Arquidiocese do Rio de Janeiro, RJ **Departamento de Imunologia, Instituto Oswaldo Cruz, Rio de Janeiro, RJ^ ***Departamento de Microbiologia, Universidade Federal de Minas Gerais, Belo Horizonte, MG ****Laboratorio de Retrovirologia, Instituto Adolfo Lutz, S o Paulo, SP *****Laboratorio de Virologia Molecular, Departamento de Genetica, Universidade Federal do Rio de Janeiro, RJ, Brasil
Code Number: OC96065
Size of Files:
Text: 18.9K
No associated graphics filesKey words: HIV-1 - genetic - antigenic - diversity - Brazil [TABLES AND FIGURES AT END OF TEXT] The Human Immunodeficiency Virus Type 1 (HIV-1) presents a high level of genetic variation leading to isolates with divergent nucleotide and amino acid sequences and distinct biological properties. This viral diversity is one of the main obstacles for the development of a universal effective vaccine. Based on HIV-1 env and gag gene sequence data, at least nine nearly equidistant genetic subtypes belonging to the M (major) group could be identified. They are designated from A through I and occurring in different geographic regions of the world (G Meyers 1994 AIDS Res Hum Retroviruses 10: 1317-1324, G Kostrikis et al. 1995 J Virol 69: 6122-6130). In addition, divergent HIV-1 viruses have been identified, and as could not be classified in any of these subtypes, were recently designated as group O (outlier) (M Van den Haesevelde et al. 1994 J Virol 68: 1586-1596, LG Gurtler et al. 1994 J Virol 68: 1581-1585, W Janssens et al. 1994 AIDS 10: 877-879). Thus, to establish a surveillance program to monitor HIV-1 diversity in sites where HIV-1 candidate vaccine will be evaluated is of paramount importance for the selection of appropriate vaccine efficacy trials. In this context, the World Health Organization Global Programme on AIDS (WHO-GPA) organized a WHO Network for HIV-1 Isolation and Characterization, providing the basis of global mechanisms for monitoring HIV-1 variability (WHO Network for HIV-1 Isolation and Characterization 1994 AIDS Res Hum Retroviruses 10: 1327-1343). Brazil is one of the vaccine trial sites selected by the WHO- GPA, together with Rwanda, Thailand and Uganda. So far, at least three different subtypes have been found in Brazil: B, F, and C. In fact, through an evaluation of 235 Brazilian isolates it was observed that subtype B was predominant (88.5%) and that only 8.9% and 1.7% of the samples were subtypes F and C, respectively (K Potts et al. 1993 AIDS 7: 1191-1197, J Louwagie et al. 1993 AIDS 7: 769-780, MG Morgado et al. 1994 AIDS Res Hum Retroviruses 10: 569-576, JC Couto-Fernandez et al. 1994 AIDS Res Hum Retroviruses 10: 1157-1163, WHO Network for HIV-1 Isolated and Characterization, 1994 AIDs Rev Hum Retrov 10: 1327-1343, B Galv o-Castro et al. 1995 Actualizaciones en SIDA 3: 173-178, E Sabino et al. 1995 2nd National Conference on Human Retroviruses and Related Infections, Washington, DC- USA, M Guimar es et al. 1995 1^o Simposio Brasileiro de Pesquisa Basica em HIV/AIDS abstract no. 17, RJ, Brazil). Interestingly, two samples (0.9%) showed to be variants resulting from a recombination between subtypes B and F (E Sabino et al. 1994 J Virol 68: 3640-6346, B Hahn et al. 1996 J Virol in press). Low levels of amino acid sequence conservation in the V3 loop were also seen between the Brazilian sequences and the HIV-1 prototypes currently in use for vaccine development. Indeed, the comparison with sequences of prevalent North American/European HIV-1 strains showed that the Brazilian subtype B sequences present amino acid replacements in some positions giving distinctive tetrameres at the tip of the V3 loop. In fact, the GWGR motif at the crown of the V3 loop was detected in 28 out of 71 (39.4%) isolates analyzed, while the highly conserved North American/European GPGR motif was observed in 25 samples (35.2%). Also, novel sequences were detected in 18 samples (25.4%) (MG Morgado 1994 in Processo de desenvolvimento de vacinas anti HIV/AIDS. Problemas e beneficios PN-DST/AIDS, Brazilian Ministry of Health). Moreover, the sequencing of the whole gp120 DNA of one Brazilian isolate with GWGR motif at the tip of the V3 loop showed an 89.1% homology of nucleic acid sequence with the prototype HIV-1 B subtype. The highest divergence was found in the V1-V3 regions (SM Costa et al. 1995 Aids Res Hum Retroviruses 11: 1243-1245). In addition, Brazilians infected with HIV-1 presented a lower specific antibody response against V3 loop peptides of predominant prototypes of HIV-1 circulating in North America and Western Europe (EW Carrow et al. 1991 AIDS Res Hum Retroviruses 7: 831-838, V Bongertz et al. 1994 Braz J Med Biol Res 27: 1225-1236). These results suggest that Brazilian HIV-1 strains have genetic and antigenic differences in comparison with North American/European prototype strains, which may hamper the success of immunoprophylatic programmes based on HIV-1 vaccine candidates currently proposed to be tested in Brazil. Therefore a Brazilian Network for HIV-1 Isolation and Characterization (BNHIC) was established in March 1993, as part of the National Programme of HIV/AIDS Vaccine Development and Evaluation, nested with Sexual Transmitted Disease/AIDS Programme of the Brazilian Ministry of Health. This network has similar organizational structure to the WHO (loc. cit.). Briefly, BNHIC was organized on a three-tier basis inclunding primary site, central reference laboratory and secondary laboratories. Initially the primary cities comprised three previously selected ones for HIV-1/AIDS vaccine evaluation located in the cities of Belo Horizonte, MG; Rio de Janeiro, RJ, and S o Paulo, SP. These sites are responsible for the selection of volunteers, collection of blood specimens and the shipment of the blood samples to the Central Reference Laboratory. The Central Reference Laboratory is the Advanced Laboratory of Public Health (LASP), Goncalo Moniz Research Center, FIOCRUZ, in Salvador, BA. This laboratory is responsible for HIV-1 isolation, expansion and distribution of biological samples and reagents to the secondary laboratories. The Central Laboratory is also the HIV isolates national repository and is also responsible for transferring of technology and traning. The biological, immunological and genetic characterization of the specimens is undertaken at the secondary laboratories: (1) AIDS and Molecular Immunology Laboratory, Department of Immunology, Oswaldo Cruz Institute, FIOCRUZ; (2) Infectious Disease Service, Department of Preventive Medicine, Federal University of Rio de Janeiro; (3) Microbiology and Immunology Laboratory, Adolfo Lutz Institute; (4) Molecular Virology Laboratory, Dept. of Genetics, Federal University of Rio de Janeiro; (5) Retrovirology Laboratory, Adolfo Lutz Institute; (6) Retrovirology Laboratory, Departament of Virology, Oswaldo Cruz Institute, FIOCRUZ; (7) Virus Laboratory, Basic Science Institute, Federal University of Minas Gerais. The main objectives of the Brazilian National Network are (1) to develop a system for continuous monitoring the genetic and antigenic variability of HIV-1 isolates from different geographic regions of Brazil; (2) to generate basic information of genetic and antigenic properties of epidemiologically relevant HIV-1 strains that will enable the selection of antigenically appropriate candidate vaccines to be evaluated and potentially used in Brazil; (3) to participate in other international HIV-1 characterization efforts as part of the WHO Network for HIV Isolation and Characterization, or on a bilateral basis of collaboration with individual international research programs. This approach, using rigorous standardized research protocols, will enable a wider ranging analysis of HIV-1 samples from different regions of Brazil. In order to achieve these goals, we have been carrying out a pilot study in one of three previously selected sites, (Rio de Janeiro, RJ) for future HIV vaccine evaluation. Initially, 16 seropositive individuals were selected for this study. HIV-1 isolation and expansion were performed according to the standard procedures described elsewhere (WHO Guidelines for Standard HIV Isolation Procedures, Geneva, 1994). Briefly, PBMC of seropositive and seronegative individuals were separated in gradient of Ficoll Hypaque, from whole blood collected using EDTA. 8 x 10^6 PBMC from seronegative donors, previously stimulated with phytohemaglutinin, were co-cultured with 2 x 10^6 patient cells in RPMI medium containing glutamine, penicilin, streptomycin and 10% fetal calf serum in the presence of 5U/ml Interleukin-2. The co-cultures were incubated at 37 C, 5% CO2, up to 24 days. Culture medium was changed each three to four days and fresh donor cells were added on the 7th^ and on the 14th days. Co-cultures were monitored for the presence of the p24 antigen each three to four days and the positive supernatants were saved as virus stock. HIV-1 isolates were biologically characterized using the methodology described elsewhere (WHO loc. cit.). Briefly, positive supernatants from primary cultures were used as the virus source to infect MT-2 cell lines. These cultures were monitored twice a week for p24 antigen and daily for syncitium formation. The isolates were also analyzed by heteroduplex mobility assay (HMA) in order to determine the subtypes of HIV-1 (E Delwart et al. 1993 Science 262: 1257-1261). The HIV-1 neutralization assay was performed following the techniques described previously (J Albert et al. 1993 AIDS Res Hum Retroviruses 9: 501-506). The age, sex, presumed mode of transmission, clinical status of the patients, as well as results of HIV-1 isolation are shown in Tables I and II. The majority of the patients were males (75%). The age ranged from 15 to 61 years. Concerning the possible transmission route, 50% were male homossexual and/or bissexual, 43% were heterossexual, and in 6.25% the mode of transmission was undeterminated. We isolated HIV-1 in 12 out of 16 (75%) samples. The p24 antigen was always detected within 12 days of co-culture. Preliminary results of biologic characterization show that seven isolates induced syncytium formation in primary co-culture (PBMC) but only three of them induced syncytium in MT-2 cell line (Table II). Only one isolate induced syncytium in MT-2 cell line alone. The rate of virus isolation and the frequency of syncytium inducing (SI) isolates were higher than that observed in a previous study (WHO loc. cit.), which could be due to the variation of the clinical status of our patients. The genetic analyses of 11 samples using HMA revealed that 10 were B and 1 was F subtypes confirming previous studies. Neutralization assays, carried out according to standard techniques in pre-activated peripheral blood mononuclear cells (PBMC) (Albert et al. loc. cit.) indicate that two of seven isolates tested were neutralized to at least 75% by their autologous plasma (28.6%) and a third isolate was neutralized to 50%. Six of the seven isolates (85.7%) were neutralized by at least one heterologous plasma from Brazilian HIV-1 infected individuals. Of 11 plasma evaluated as to their potency in neutralizing heterologous primary Brazilian HIV-1 isolates, nine (82%) were able to neutralize 75% of at least one isolate. All isolates tested (7/7 = 100%) were susceptible to > 75% neutralization by a pool of plasma from the patients envolved in this study. Of 12 plasma tested, nine (75%) were able to neutralize the reference isolate HIV-1 MN. These preliminary results indicate that one of the isolates (RJ95006) appears to be quite resistent to neutralization (autologous and heterologous), while another isolate (RJ95005) appears to be highly susceptible to neutralization, with all other isolates showing intermediate susceptibility. In summary, neutralization of Brazilian primary HIV-1 isolates appears to be similar to neutralization of other primary HIV-1 isolates described in the United States (PD Souza et al. 1995 AIDS 9: 867-874, JP Moore et al. 1995 J Virol 69: 122-130) and Europe (Eva- Maria Fen o 1994 personal communication and 9eme col Cent gardes 103-107). Some of the individuals enrolled in this pilot study did not fullfill the inclusion criteria required to participate in this research project. Most of them were infected for more than two years, including two cases of AIDS with CD4 cell counts below 200 cells/mm^3. In addition, some of them were under antiviral treatment. Thus, it is important to point out that the recruitment of individuals not strictly meeting the inclusion criteria in this study, such as: (a) be a recent seroconverted or to have less than two years of infection; (b) have CD4 cell counts above 200 cells/mm^3 and (c) not be under antiviral treatment, could jeopardize the information required for future vaccine efficacy trials. Nevertheless, this pilot study has demonstrated the feasibility of the BNHIC, as well as the possibility of the HMA usage for large scale molecular epidemiological studies in Brazil. This will enable us to establish a sentinel surveillance on the prevalence and the dynamic of different HIV-1 genetic subtypes in various population groups in Brazil. Finally, we should emphasize that a well organized and integrated national effort is of paramount importance for establishing a successful surveillance system to monitor HIV-1 diversity on a nationwide scale.
Acknowledgements: to the techinical assistance of Mrs Jurema Carrilho. Partially supported by World Health Organization, Global Programme on AIDS UNDP/World Bank/Brazilian Ministry of Health STD/AIDS Program; Programa Institucional de AIDS/FIOCRUZ, Bank of Brazil Foundation and National Research Council, (CNPq). +Corresponding author. Fax: 55-71-359.2255 ++Dirceu Greco, Paulo Cesar Peregrino Ferreira (UFMG), Jose Carvalheiro (Ministerio da Saude), Bernardo Galv o-Castro, Jose Carlos Couto-Fernandez (FIOCRUZ - BA), Frits Sutmoller, Vera Bongertz, Mariza Morgado, Jose P Simonetti (FIOCRUZ - RJ), Mauro Schechter, Amilcar Tanuri (UFRJ), Luiz Fernando Brigido de Macedo, Ester Sabino, Mirthes Ueda (Inst. Adolfo Lutz, SP).
Received 7 December 1995 TABLE I Epidemiological and clinical data and CD^4 ^+ cell counts from individuals from Rio de Janeiro, RJ, Brazil
Patients Sex Age PTR^a Clinical status CD4/mm^3 ------------------------------------------------------- RJ001-95 M 35 homo asympt 670 RJ002-95 M 28 bi AIDS 519 RJ003-95 M 15 homo asympt 379 RJ004-95 M 61 ? AIDS <50 RJ005-95 M 58 homo AIDS 191 RJ006-95 M 26 hetero asympt ND RJ007-95 F 30 hetero asympt 673 RJ008-95 F 42 hetero asympt 473 RJ009-95 F 43 hetero asympt ND RJ010-95 M 37 hetero asympt 612 RJ011-95 M 49 bi asympt 1098 RJ012-95 M 28 homo asympt 330 RJ013-95 M 45 hetero asympt 1191 RJ014-95 M 53 bi asympt 115 RJ015-95 M 32 bi asympt 549 RJ016-95 F 48 hetero asympt 689 a: presumed transmission route (homo= male homosexual; bi= male bisexual; hetero= heterosexual) TABLE II Genetic and phenotipic characterization of HIV-1 isolates from individuals from Rio de Janeiro, RJ, Brazil
Neutralization
HIV CPE^a TCID^b Suscept-
Potency^d Sub-
ibility^c types
Patients isola- PBMC MT-2 50% aut het het HMA^e
tion
--------------------------------------------------------------
RJ001-95 Y + + <2 NA NA + B
RJ002-95 Y + - 50 + + + B
RJ003-95 Y + - <2 NA NA + F
RJ004-95 Y + - 750 - + + B
RJ005-95 Y - - 750 + + + B
RJ006-95 Y - + 250 - - + B
RJ007-95 N - - NA^f NA NA ND
B
RJ008-95 N - - NA NA NA ND B
RJ009-95 Y + - 30 - + - B
RJ010-95 Y + + 50 - + - B
RJ011-95 Y - - 10 NA NA + B
RJ012-95 Y + + ND^g ND ND ND
ND
RJ013-95 N - - ND ND ND ND ND
RJ014-95 Y - - ND ND ND ND ND
RJ015-95 Y - - ND ND ND ND ND
RJ016-95 N - - ND ND ND ND NDCopyright 1996 Fundacao Oswaldo Cruz
|
| |||||||||
